Sage Therapeutics’ (SAGE) Neutral Rating Reiterated at Wedbush

Wedbush reissued their neutral rating on shares of Sage Therapeutics (NASDAQ:SAGE) in a research note released on Wednesday,Benzinga reports. Wedbush currently has a $6.00 price target on the biopharmaceutical company’s stock.

SAGE has been the topic of several other reports. Canaccord Genuity Group decreased their price objective on shares of Sage Therapeutics from $9.00 to $8.00 and set a “hold” rating on the stock in a report on Wednesday. Royal Bank of Canada raised shares of Sage Therapeutics from an “underperform” rating to a “sector perform” rating and set a $4.00 price target on the stock in a research note on Thursday, November 21st. Oppenheimer decreased their price target on shares of Sage Therapeutics from $9.00 to $8.00 and set a “market perform” rating on the stock in a research note on Wednesday, October 30th. TD Cowen decreased their price target on shares of Sage Therapeutics from $10.00 to $9.00 and set a “hold” rating on the stock in a research note on Thursday, November 21st. Finally, HC Wainwright reissued a “neutral” rating and issued a $12.00 price target (down from $14.00) on shares of Sage Therapeutics in a research note on Wednesday. Three research analysts have rated the stock with a sell rating, sixteen have issued a hold rating and two have given a buy rating to the company. According to MarketBeat.com, Sage Therapeutics currently has an average rating of “Hold” and an average target price of $9.65.

Sage Therapeutics Stock Performance

SAGE stock opened at $7.14 on Wednesday. The firm has a market cap of $438.97 million, a PE ratio of -1.28 and a beta of 0.94. Sage Therapeutics has a one year low of $4.62 and a one year high of $26.25. The firm’s fifty day moving average is $6.40 and its 200 day moving average is $6.91.

Sage Therapeutics (NASDAQ:SAGE) last posted its quarterly earnings data on Tuesday, February 11th. The biopharmaceutical company reported ($1.56) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.54) by ($0.02). Sage Therapeutics had a negative net margin of 317.29% and a negative return on equity of 50.29%. Research analysts predict that Sage Therapeutics will post -6.46 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Sage Therapeutics

Institutional investors have recently made changes to their positions in the stock. Picton Mahoney Asset Management grew its holdings in shares of Sage Therapeutics by 126.0% in the fourth quarter. Picton Mahoney Asset Management now owns 6,423 shares of the biopharmaceutical company’s stock valued at $35,000 after purchasing an additional 3,581 shares in the last quarter. KLP Kapitalforvaltning AS purchased a new stake in shares of Sage Therapeutics during the 4th quarter worth approximately $49,000. Ieq Capital LLC purchased a new stake in shares of Sage Therapeutics during the 4th quarter worth approximately $57,000. China Universal Asset Management Co. Ltd. lifted its position in shares of Sage Therapeutics by 66.1% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 11,742 shares of the biopharmaceutical company’s stock worth $85,000 after buying an additional 4,672 shares during the last quarter. Finally, Creative Planning purchased a new stake in shares of Sage Therapeutics during the 3rd quarter worth approximately $88,000. 99.22% of the stock is currently owned by institutional investors and hedge funds.

About Sage Therapeutics

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.